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Background: The total incidence of invasive menin-
gococcal disease (IMD) in Europe has been declining 
in recent years; however, a rising incidence due to 
serogroup W (MenW), predominantly sequence type 
11 (ST-11), clonal complex 11 (cc11), was reported in 
some European countries. Aim: The aim of this study 
was to compile the most recent laboratory surveillance 
data on MenW IMD from several European countries to 
assess recent trends in Europe. Methods: In this obser-
vational, retrospective study, IMD surveillance data 
collected from 2013–17 by national reference laborato-
ries and surveillance units from 13 European countries 
were analysed using descriptive statistics. Results: 
The overall incidence of IMD has been stable during 
the study period. Incidence of MenW IMD per 100,000 
population (2013: 0.03; 2014: 0.05; 2015: 0.08; 2016: 
0.11; 2017: 0.11) and the proportion of this serogroup 
among all invasive cases (2013: 5% (116/2,216); 2014: 
9% (161/1,761); 2015: 13% (271/2,074); 2016: 17% 
(388/2,222); 2017: 19% (393/2,112)) continuously 
increased. The most affected countries were England, 
the Netherlands, Switzerland and Sweden. MenW was 
more frequent in older age groups (≥ 45 years), while 
the proportion in children (< 15 years) was lower than in 
other age groups. Of the culture-confirmed MenW IMD 
cases, 80% (615/767) were caused by hypervirulent 
cc11. Conclusion: During the years 2013–17, an increase 
in MenW IMD, mainly caused by MenW cc11, was 
observed in the majority of European countries. Given 
the unpredictable nature of meningococcal spread and 
the epidemiological potential of cc11, European coun-
tries may consider preventive strategies adapted to 
their contexts.
Introduction
The total incidence of invasive meningococcal disease 
(IMD) in Europe has been declining in recent years; 
however, a rising incidence of IMD caused by serogroup 
W (MenW) was reported in the United Kingdom (UK) in 
2009 [1], then the Netherlands [2] and Sweden [3], fol-
lowing the spread of MenW IMD in South America since 
2004 [4]. The isolated strains predominantly belong to 
the multilocus sequence typing (MLST) defined hyper-
virulent clonal complex 11 (cc11).
Some patients with MenW:cc11 infection have been 
reported to present with gastrointestinal symptoms, 
which is uncommon for patients with IMD caused by 
meningococci of other serogroups [5]. The case fatality 
rate (CFR) of MenW IMD was described to be more than 
twice that of IMD caused by other serogroups, and the 
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proportion of MenW:cc11 in all IMD cases was found to 
be higher in adults than in infants [6].
In response to the rapid expansion of hypervirulent 
MenW:cc11 in the UK, a MenACWY conjugate vaccina-
tion programme was introduced in August 2015 for all 
adolescents 13–18 years of age, as well as university 
students up to 25 years of age [7]. In Italy, the pro-
gramme was introduced for those 12–18 years of age in 
2017 [8] and in the Netherlands for those 13–14 years 
of age in 2018, with a catch-up vaccination up to the 
age of 18 [9,10]. MenACWY vaccination has been rec-
ommended in Greece since 2011 for those 11–16 years 
of age [11] and in Austria since 2012 for those 10–13 
year of age [12]. In contrast to earlier IMD epidemics 
where vaccines were not available or became available 
near the end of the epidemic, such as in New Zealand 
in the 1990s, several vaccines against MenACWY have 
been approved and are available in Europe [13,14].
The aim of the present study was to compile the most 
recent laboratory surveillance data on MenW IMD from 
several European countries to assess recent trends in 
Europe.
Methods
Setting and data collection
All national reference laboratories active in the 
European Meningococcal and Haemophilus Disease 
Society (EMGM) were invited to a workshop on sero-
group W and Y meningococci in Europe, taking place 
in November 2016. This workshop was organised using 
EMGM’s institutional support from Pfizer, though the 
company did not have any influence on the outline or 
content of the meeting.
Reference laboratories from 14 countries were asked to 
participate in this study. The Czech Republic, England, 
Finland, Germany, Greece, Italy, the Netherlands, 
Norway, Poland, Portugal, Spain, Sweden and 
Switzerland provided the following data in an Excel 
spreadsheet: the number and age distribution of IMD 
cases (total and MenW), laboratory surveillance rate of 
the reported cases and data on cc11 as a surrogate for 
the W lineages from 2013–16. The participating coun-
tries represented over two thirds of the total combined 
European Union (EU)/European Free Trade Association 
(EFTA) population.
After identifying and correcting missing or inconsist-
ent numbers, the dataset was compiled and analysed. 
IMD numbers were based on publicly available national 
reporting, which is mandatory in all 13 participating 
countries. On average, 90% of the reported IMD cases 
were laboratory confirmed by the national reference 
laboratories, ranging from 60–100% depending on 
the country. To achieve a high quality standard on the 
serogrouping data, only MenW cases analysed by ref-
erence laboratories were included in the analysis, as 
Table 
Number of invasive meningococcal disease cases and number and incidence of laboratory-confirmed MenW cases, by 
country, 13 EMGM-member countries, 2013–2017 (n = 10,385 cases)
Country
Number of reported IMD cases MenW cases MenW incidence
AAPC p value
2013 2014 2015 2016 2017 2013 2014 2015 2016 2017 2013 2014 2015 2016 2017
Englanda 726 628 797 804 704 76 117 201 224 195 0.14 0.22 0.37 0.41 0.35 23% < 0.001
Germanyb 345 278 287 339 281 10 10 10 26 26 0.01 0.01 0.01 0.03 0.03 35% < 0.001
Spain 262 146 210 250c 261c 6 6 6 21 28 0.01 0.01 0.01 0.05 0.06 62% < 0.001
Polanda 235 180 198 157 204 3 4 7 7 9 < 0.01 0.01 0.02 0.02 0.02 29% 0.056
Italy 172 165 189 228 175 5 8 7 13 9 < 0.01 0.01 0.01 0.02 0.01 17% 0.165
Netherlandsa 117 77 85 153 198 7 1 9 50 80 0.04 < 0.01 0.05 0.29 0.47 133% < 0.001
Sweden 74 49 53 62 49 3 2 11 18 17 0.03 0.02 0.11 0.18 0.17 58% < 0.001
Greeceb 68 66 57 53 42 2 2 0 1 1 0.02 0.02 0 0.01 0.01 -22% 0.404
Portugal 61 54 66 40 44 1 0 0 1 2 0.01 0 0 0.01 0.02 50% 0.300
Czech 
Republicb 59 42 48 43 68 0 2 3 4 3 0 0.02 0.03 0.04 0.03 42% 0.113
Switzerland 50 37 43 51 53 3 6 13 15 18 0.04 0.07 0.16 0.18 0.21 44% <0.001
Norway 27 18 19 23 17 0 2 0 5 5 0 0.04 0 0.10 0.10 86% 0.016
Finlandb 20 21 22 19 16 0 1 4 3 0 0 0.02 0.07 0.05 0 13% 0.628
Total 2,216 1,761 2,074 2,222 2,112 116 161 271 388 393 0.03 0.05 0.08 0.11 0.11 35% < 0.001
AAPC: average annual percentage change; EMGM: European Meningococcal and Haemophilus Disease Society; IMD: invasive meningococcal 
disease; MenW: serogroup W Neisseria meningitidis.
a Based on laboratory-confirmed cases only.
b Reported numbers were based on a database merged from statutory notifications and laboratory surveillance.
c Extrapolated from the available laboratory surveillance data representing ca 80% of the notified cases, as notification data was not yet 
available.
3www.eurosurveillance.org
Figure 1
Mean annual incidence of (A) invasive meningococcal disease (IMD) and (B) serogroup W N. meningitidis (MenW) IMD 
per 100,000 population and the proportion of (C) MenW IMD cases and (D) MenW clonal complex 11 IMD casesa, by 
country, 13 EMGM-member countries, 2013–2017
A. B.
D.
IMD Incidence 
per 100,000 population
> 1.0
0.6 - 1.0
0.4 - 0.59
< 0.4
Proportion MenW
> 20%
10 - 20%
5 - 9%
< 5%
Proportion cc11
> 90%
80 - 90%
50 - 79%
< 50%
MenW Incidence 
per 100,000 population
> 0.20
0.10 - 0.20
0.02 - 0.09
< 0.02
C.
cc11: clonal complex 11; EMGM: European Meningococcal and Haemophilus Disease Society; IMD: invasive meningococcal disease; MenW: 
serogroup W Neisseria meningitidis.
a 2013–16.
Map: Blank map of Europe cropped.svg by Leftcry / CC-BY-2.5.
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serogrouping in peripheral laboratories is not always 
performed by standardised methods. Reference labo-
ratories reported the number of cases according to 
the laboratory criteria of the EU case definitions [15]. 
Typing data were matched at different levels with the 
statutory notification data. Preliminary 2017 data were 
collected on IMD and MenW cases, as at the time of 
writing sequence typing data was not yet available for 
many countries.
In England, national reporting is based on laboratory-
confirmed cases only; therefore, only such cases were 
included in this study [16]. Dutch and Polish data used 
in this study were also based on laboratory-confirmed 
cases. In the Czech Republic, Finland, Germany and 
Greece the reported numbers were based on mandatory 
notification data merged with laboratory surveillance 
data in a national database. As notification data were 
not available for the number of Spanish IMD cases in 
2016–17, this number was extrapolated from the avail-
able laboratory surveillance data, representing approx-
imately 80% of the notified cases in the years 2013–15. 
Population and age distribution data from 12 of the 13 
countries were obtained from Eurostat [17]. Data on the 
English population were acquired from the UK Office 
for National Statistics [18]. As more recent data were 
not yet available, the English population number from 
2016 was used for 2017.
Typing
The serogroup was determined by slide agglutination 
or PCR. Depending on the country, MLST—either on 
Sanger sequence or next generation sequencing data—
was used to determine if strains belonged to cc11. The 
Bacterial Isolate Genome Sequence Database (BIGSdb) 
was used for data matching [19].
Statistics
Average annual percentage change in incidence was 
calculated for each country using Poisson regression. A 
p value < 0.05 was considered statistically significant.
Figure 2
Incidence of invasive meningococcal disease due to serogroup W Neisseria meningitidis per 100,000 population, by year and 
country, 13 EMGM-member countries, 2013–2017 (n = 1,329)
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EMGM: European Meningococcal and Haemophilus Disease Society; MenW: serogroup W Neisseria meningitidis.
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Results
Incidence of invasive meningococcal diseases 
cases
From 2013–17, a total of 10,385 IMD cases were reported 
by the 13 participating countries. Accounting for the 
slightly growing population (2013: 355.7 million, 2014: 
357.4 million, 2015: 358.5 million, 2016: 360.1 million, 
2017: 360.8 million), this corresponds to an average 
annual incidence of 0.58 cases per 100,000 popula-
tion. Serogroup W was responsible for 1,329 (13%) of 
the total number of IMD cases (Table 1).
The average annual incidence of overall IMD and MenW 
IMD varied considerably between individual coun-
tries. For IMD, the incidence per 100,000 population 
ranged from 0.31 cases in Italy to 1.34 in England. For 
MenW IMD, the incidence per 100,000 population var-
ied from 0.008 cases in Portugal to 0.17 cases in the 
Netherlands and 0.30 cases in England (Figure 1).
While the annual incidence of IMD remained stable in 
Europe from 2013–17 (2013: 0.62, 2014: 0.49, 2015: 
0.58, 2016: 0.62, 2017: 0.59; average annual percentage 
change (AAPC): 1%; p = 0.214), the incidence of MenW 
IMD (2013: 0.03, 2014: 0.05, 2015: 0.08, 2016: 0.11, 
2017: 0.11; AAPC: 35%; p < 0.001) and the proportion 
of this serogroup among all IMD (2013: 5%, 2014: 9%, 
2015: 13%, 2016: 17%, 2017: 19%; p = 0.002) increased 
significantly during this time. Significant increases in 
MenW incidence were observed in the Netherlands 
(AAPC: 133%; p < 0.001), Norway (AAPC: 86%; p = 
0.016), Spain (AAPC: 62%; p < 0.001), Sweden (AAPC: 
58%; p < 0.001), Switzerland (AAPC: 44%; p < 0.001), 
Germany (AAPC: 35%; p < 0.001) and England (AAPC: 
23%; p < 0.001). The latter represents 61% of the total 
number of reported MenW cases in the 13 European 
countries during the overall study period. Though not 
statistically significant, there were also trends towards 
an increasing incidence in some other countries. (Table 
1, Figure 2, Figure 3).
Figure 3
Percentage of serogroup W Neisseria meningitidis of all invasive meningococcal disease cases, 13 EMGM-member countries, 
2013–2017
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The proportion of MenW among all IMD cases varied 
considerably between countries. The proportion of 
MenW was lowest in Portugal (2%, 4/265), Greece (2%, 
6/286) and Poland (3%, 30/974), while it was highest 
in Switzerland (24%, 55/234), the Netherlands (23%, 
147/630) and England (22%, 813/3,659) (Figure 1).
Age distribution
In 2016, MenW IMD cases were overrepresented in the 
age groups 15–24 years (18% of all IMD cases, 73/408), 
45–64 years (24%, 75/316) and ≥  65 years (34%, 
137/405), while the percentage of MenW IMD cases 
in the vaccination target group of children ≤  14 years 
(10%, 84/870), as well as those 25–44 years of age 
(9%, 19/223), was lower than the average. However, 
the MenW IMD incidence was still highest in children 
<  5 years of age (0.8/100,000 population). The low-
est proportion of MenW IMD was observed in the age 
group 5–14 years (8%, 16/209). In absolute numbers, 
most MenW IMD cases were registered in the age group 
≥ 65 years (n = 137). (Figure 4)
Sequence typing
Of the 936 reported cases of MenW IMD between 
2013–16, 767 (82%) strain isolates were analysed by 
MLST and 615 (80%) belonged to cc11. The proportion 
of cc11 increased from 64% (64/100) in the year 2013 to 
86% (265/307) in the year 2016 (Figure 5)
The proportion of sequence-typed MenW strains that 
belonged to cc11 varied considerably among countries, 
ranging from one in six in the Czech Republic to 31 in 
34 in Switzerland (Figure 1).
Discussion
Laboratory surveillance and national health authority 
data from 13 European countries revealed an increase 
in MenW IMD in the period 2013–17. The MenW IMD 
incidence differed between participating countries 
and was highest in England and the Netherlands, as 
reported previously [1,2]. Significantly increasing inci-
dences and proportions of MenW IMD among all IMD 
were observed in the majority of the participating 
Figure 4
Number and incidence per 100,000 population of invasive meningococcal disease (IMD) caused by serogroup W Neisseria 
meningitidis (MenW), by age group, and percentage of MenW of all IMD cases, 13 EMGM-member countries, 2016
0
5
10
15
20
25
30
35
40
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
< 1 1–4 5–14 15–24 25–44 45–64 > 65
Percentage M
enW
 of all IM
D cases M
en
W
 c
as
es
 p
er
 1
00
,0
00
 p
op
ul
at
io
n
MenW cases per 100,000 population
Age group
(n = 28) (n = 40) (n = 16) (n = 73) (n = 19) (n = 75) (n = 137)
Percentage MenW of all IMD cases 
EMGM: European Meningococcal and Haemophilus Disease Society; IMD: invasive meningococcal disease; MenW: serogroup W Neisseria 
meningitidis.
7www.eurosurveillance.org
countries, while the case numbers in other countries 
were too small to assess significance.
The increase seen in Europe follows a rising incidence of 
MenW in South America since 2004 [4]. More recently, a 
rising MenW incidence has been observed in Australia 
since 2013 [6] and in Canada since 2015 [20]. An epi-
demic spread of this MenW strain can be assumed for 
regions in the Americas, Australia and Europe. Notably, 
in 2015 an international outbreak related to the World 
Scout Jamboree in Japan was caused by the MenW:cc11 
strain from the UK [21]. This was observed previously 
for other meningococci serogroups, including sero-
group C:cc11 in the 1990s [22], serogroup A since the 
1960s [23] and serogroup B since the 1970s [24]. The 
dynamics of such intercontinental epidemic waves is 
hardly predictable and the mechanisms behind differ-
ent dynamics of spread are still unclear. Typing by next 
generation sequencing revealed the relatedness of the 
MenW strains from South America, England [25] and 
the Netherlands [2]. It is possible that cc11 in general 
has a particular capacity to spread between countries, 
as these strains have shown this already in the past 
[21,26-28]. A possible experimental hypothesis is that 
cc11 strains are maintained in the population by fre-
quent transmission events, despite a short duration of 
carriage [29].
It is noteworthy that the majority of cases of MenW 
IMD in Europe between 2013–16 occurred in those ≥ 45 
years of age, with the highest number of cases found in 
patients ≥ 65 years of age. It is unclear whether this is 
the result of a circulation of strains in those ≥ 45 years 
of age or if colonised children and teenagers are the 
major source of transmission to the older population. 
Indeed, carriage of meningococci is most frequent in 
adolescents and young adults, with a peak around the 
age of 20 that decreases with age; however, studies 
on carriage of meningococci in adults and the elderly 
are rare [30]. From the existing evidence, it may be 
suggested that despite infrequent disease, carriage in 
adolescents and young adults is much more abundant 
than in infants and toddlers [30]. Whether or not trans-
mission occurs mainly within the affected age strata 
remains unclear. New carriage studies among all age 
groups are needed to inform about the MenW spread 
in Europe.
MenW is vaccine preventable and potent conjugate 
vaccines have been approved for use in Europe. Many 
European countries use meningococcal C conjugate 
vaccines for infant immunisation. A general booster 
vaccination using a quadrivalent MenACWY vaccine—
as introduced in Greece [11], Austria [12], the UK [7], 
Italy [8] and the Netherlands [9,10]—boosters the wan-
ing MenC antibody titres [31] and provides immunity 
towards MenA, MenW and MenY.
As target groups and coverages vary in different coun-
tries (e.g. case numbers in some countries are low) and 
some programs were introduced quite recently, it is still 
too early to conclude on the effect of the vaccinations. 
In theory, by vaccinating adolescents, acquisition of 
carriage should be prevented and herd protection 
induced. This may be a cost-effective approach, as it 
might not be possible to immunise all groups. Public 
health decision-makers should be aware of the rise of 
MenW and, taking into account the situations in their 
respective countries, they may consider including 
quadrivalent meningococcal ACWY in their adolescent 
vaccination programmes.
The present study demonstrates the power of labora-
tory networks to provide surveillance data on short 
notice. The EMGM has already proved to be a function-
ing laboratory network on earlier occasions. The pre-
sent survey relied on Sanger sequencing information, 
as next generation sequencing has not been rolled 
out to a sufficient extent in all countries. However, the 
example of the MenW spread shows that for particular 
questions this technique is indispensable. The causa-
tive agent is a particular derivative of the cc11, which 
can only be elucidated by high-resolution techniques 
[3]. The function of BIGSdb as a platform allowing the 
integration of genome sequence data was first vali-
dated using meningococcal sequence data as an exam-
ple [19]. Future European-level meningococcal disease 
surveillance databases linking public health reporting 
data with high-resolution sequencing data would be 
Figure 5
Total serogroup W Neisseria meningitidis (MenW) 
invasive meningococcal disease (IMD) cases, cultured 
MenW sequence-typed cases and MenW:cc11 cases, 13 
EMGM-member countries, 2016
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beneficial for outbreak detection. The respective infor-
mation technology is available; however, clarification 
of data protection issues and an unambiguous nomen-
clature is a prerequisite.
One limitation of this study is the incomplete coverage 
of Europe. Only 13 of the 32 EU/EFTA countries joined 
this project. However, more than two thirds of the pop-
ulation of the EU/EFTA area was addressed. It should 
be noted that in the UK, only England participated. 
Further, because of varying reporting and surveillance 
structures, the ways that data were obtained differed 
between countries, as did the laboratory surveillance 
coverage. Under-reporting may also have occurred 
on different levels, as cases of IMD could have been 
misdiagnosed or misclassified [32]. In addition, cases 
of MenW IMD may have been missed if they were not 
serogrouped by a national reference laboratory.
Conclusion
In conclusion, this study showed a concerning trend of 
increasing MenW incidence in several European coun-
tries, which needs to be followed carefully. Revision 
of vaccination schedules that takes into account an 
individual country’s situation may be considered to 
counteract this trend. Furthermore, this study shows 
the strength of laboratory networks to combine and 
evaluate data on short notice. In the case of increasing 
MenW IMD, serogrouping and basic typing data were 
indispensable for the evaluation.
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